Schedule 13G ownership disclosure
Protalix BioTherapeutics Inc
Security class unavailable · CUSIP: 74365A309
Event date: 2021-06-14
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 2,034,117
- Percent of class
- 4.4700%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-21-081244
- Form type
- SC 13G
- Filer
- Dexcel Pharma Technologies Ltd.
- CIK
- CIK 1720007
- Filed
- Jun 15, 2021
- Reporting period
- Jun 14, 2021
- Description
- Schedule 13G beneficial ownership